Indian Pharma
-
{
- All
- News
- Videos
-
India Set To Get Dengue Vaccine Qdenga Soon: Doctors Explain What To Expect
- Thursday April 2, 2026
- Health | Written by Rupashi Chhabra
India is set to get a dengue vaccine named Qdenga to tackle the disease burden that it poses. Dr Rashmi Khadapkar and Dr Neha Rastogi explain what people can expect from this announcement.
-
www.ndtv.com
-
Iran War Impact: Hospital Bills, Medicines Could Soon Cost More In India
- Thursday March 26, 2026
- India News | NDTV
India's medical devices and pharma sectors import a large share of raw materials, active ingredients and specialised components
-
www.ndtv.com
-
Weight Loss Injection For ₹900? Three Pharma Firms Launch Affordable Semaglutide, Check Prices
- Saturday March 21, 2026
- Feature | Edited by Nikhil Pandey
Indian pharmaceutical companies have launched affordable versions of semaglutide injections following a patent expiry, significantly lowering costs for diabetes and weight management treatment and improving access for millions of patients.
-
www.ndtv.com
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
- Saturday March 21, 2026
- Health | Indo-Asian News Service
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
www.ndtv.com
-
Central Drugs Body Revamps Testing Permissions To Fast-Track Drug Approvals in India
- Thursday February 26, 2026
- Health | Written by Shreya Goswami
India's drug regulator Central Drugs Standard Control Organization has revised testing permission norms to speed up approvals. From June 1, 2026, companies can start lab testing immediately after application, a step aimed at reducing delays while mai
-
www.ndtv.com
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
- Thursday February 26, 2026
- Health | Written by Shreya Goswami
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
www.ndtv.com
-
India-US Trade Deal Likely To Offer Tariff Relief On Exported Medicines
- Wednesday February 11, 2026
- Health | Indo-Asian News Service
India's pharmaceutical industry has welcomed the interim trade agreement framework between India and the US, which offers tariff relief on medicines and several other Indian exports.
-
www.ndtv.com
-
Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In First-Line Treatment
- Tuesday February 10, 2026
- Health | Indo-Asian News Service
AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation to sell and distribute Durvalumab solution for infusion used in cancer treatment.
-
www.ndtv.com
-
Indian Pharmaceutical Body Signs 3 Memorandums To Strengthen Drug Safety And Quality Standards
- Monday February 9, 2026
- Health | Press Trust of India
The Indian Pharmacopoeia Commission has signed memoranda with the Goa State Pharmacy Council, Quality Council of India, and HLL Infra Tech Services to strengthen drug safety, quality assurance and pharmacovigilance.
-
www.ndtv.com
-
India Set To Get Dengue Vaccine Qdenga Soon: Doctors Explain What To Expect
- Thursday April 2, 2026
- Health | Written by Rupashi Chhabra
India is set to get a dengue vaccine named Qdenga to tackle the disease burden that it poses. Dr Rashmi Khadapkar and Dr Neha Rastogi explain what people can expect from this announcement.
-
www.ndtv.com
-
Iran War Impact: Hospital Bills, Medicines Could Soon Cost More In India
- Thursday March 26, 2026
- India News | NDTV
India's medical devices and pharma sectors import a large share of raw materials, active ingredients and specialised components
-
www.ndtv.com
-
Weight Loss Injection For ₹900? Three Pharma Firms Launch Affordable Semaglutide, Check Prices
- Saturday March 21, 2026
- Feature | Edited by Nikhil Pandey
Indian pharmaceutical companies have launched affordable versions of semaglutide injections following a patent expiry, significantly lowering costs for diabetes and weight management treatment and improving access for millions of patients.
-
www.ndtv.com
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
- Saturday March 21, 2026
- Health | Indo-Asian News Service
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
www.ndtv.com
-
Central Drugs Body Revamps Testing Permissions To Fast-Track Drug Approvals in India
- Thursday February 26, 2026
- Health | Written by Shreya Goswami
India's drug regulator Central Drugs Standard Control Organization has revised testing permission norms to speed up approvals. From June 1, 2026, companies can start lab testing immediately after application, a step aimed at reducing delays while mai
-
www.ndtv.com
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
- Thursday February 26, 2026
- Health | Written by Shreya Goswami
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
www.ndtv.com
-
India-US Trade Deal Likely To Offer Tariff Relief On Exported Medicines
- Wednesday February 11, 2026
- Health | Indo-Asian News Service
India's pharmaceutical industry has welcomed the interim trade agreement framework between India and the US, which offers tariff relief on medicines and several other Indian exports.
-
www.ndtv.com
-
Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In First-Line Treatment
- Tuesday February 10, 2026
- Health | Indo-Asian News Service
AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation to sell and distribute Durvalumab solution for infusion used in cancer treatment.
-
www.ndtv.com
-
Indian Pharmaceutical Body Signs 3 Memorandums To Strengthen Drug Safety And Quality Standards
- Monday February 9, 2026
- Health | Press Trust of India
The Indian Pharmacopoeia Commission has signed memoranda with the Goa State Pharmacy Council, Quality Council of India, and HLL Infra Tech Services to strengthen drug safety, quality assurance and pharmacovigilance.
-
www.ndtv.com